Antifungal resistance: Emerging mechanisms and implications (Review)

Bongomin F, Gago S, Oladele RO and Denning DW: Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel). 3:572017. View Article : Google Scholar : PubMed/NCBI

Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG and White TC: Hidden killers: Human fungal infections. Sci Transl Med. 4:165rv13. 2012. View Article : Google Scholar : PubMed/NCBI

Denning DW: Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 24:e428–e438. 2024. View Article : Google Scholar : PubMed/NCBI

Fisher MC, Hawkins NJ, Sanglard D and Gurr SJ: Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 360:739–742. 2018. View Article : Google Scholar : PubMed/NCBI

Enoch DA, Yang H, Aliyu SH and Micallef C: The changing epidemiology of invasive fungal infections. Methods Mol Biol. 1508:17–65. 2017. View Article : Google Scholar

Lee Y, Puumala E, Robbins N and Cowen LE: Antifungal drug resistance: Molecular mechanisms in Candida albicans and beyond. Chem Rev. 121:3390–3411. 2020. View Article : Google Scholar : PubMed/NCBI

Maligie MA and Selitrennikoff CP: Cryptococcus neoformans resistance to echinocandins:(1, 3) β-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother. 49:2851–2856. 2005. View Article : Google Scholar : PubMed/NCBI

Berkow EL and Lockhart SR: Fluconazole resistance in Candida species: A current perspective. Infect Drug Resist. 10:237–245. 2017. View Article : Google Scholar

Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M and Jones RN: Twenty years of the SENTRY antifungal surveillance program: Results for Candida species from 1997–2016. Open Forum Infect Dis. 6 (Suppl 1):S79–S94. 2019. View Article : Google Scholar : PubMed/NCBI

Wuyts J, Van Dijck P and Holtappels M: Fungal persister cells: The basis for recalcitrant infections? PLoS Pathog. 14:e10073012018. View Article : Google Scholar : PubMed/NCBI

Berman J and Krysan DJ: Drug resistance and tolerance in fungi. Nat Rev Microbiol. 18:319–331. 2020. View Article : Google Scholar

Rosenberg AJ, Ene IV, Bibi M, Zakin S, Segal ES, Ziv N, Dahan AM, Colombo AL, Bennett RJ and Berman J: Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia. Nat Commun. 9:24702018. View Article : Google Scholar : PubMed/NCBI

Cowen LE, Sanglard D, Howard SJ, Rogers PD and Perlin DS: Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med. 5:a0197522015. View Article : Google Scholar

Lee Y, Robbins N and Cowen LE: Molecular mechanisms governing antifungal drug resistance. NPJ Antimicrob Resist. 1:52023. View Article : Google Scholar

Revie NM, Iyer KR, Robbins N and Cowen LE: Antifungal drug resistance: Evolution, mechanisms and impact. Curr Opin Microbiol. 45:70–76. 2018. View Article : Google Scholar

Shapiro RS, Robbins N and Cowen LE: Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev. 75:213–267. 2011. View Article : Google Scholar : PubMed/NCBI

Patra S, Raney M, Pareek A and Kaur R: Epigenetic regulation of antifungal drug resistance. J Fungi (Basel). 8:8752022. View Article : Google Scholar : PubMed/NCBI

Perea S and Patterson TF: Antifungal resistance in pathogenic fungi. Clin Infect Dis. 35:1073–1080. 2002. View Article : Google Scholar : PubMed/NCBI

Hosseini P, Keniya MV, Sagatova AA, Toepfer S, Müller C, Tyndall JDA, Klinger A, Fleischer E and Monk BC: The molecular basis of the intrinsic and acquired resistance to azole antifungals in Aspergillus fumigatus. J Fungi (Basel). 10:8202024. View Article : Google Scholar : PubMed/NCBI

Rosam K, Monk BC and Lackner M: Sterol 14α-Demethylase ligand-binding pocket-mediated acquired and intrinsic azole resistance in fungal pathogens. J Fungi (Basel). 7:10.3390/jof7010001. 2021. View Article : Google Scholar

Caramalho R, Tyndall JDA, Monk BC, Larentis T, Lass-Flörl C and Lackner M: Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved aminoacid substitution of the lanosterol 14α-demethylase. Sci Rep. 7:158982017. View Article : Google Scholar : PubMed/NCBI

Leonardelli F, Macedo D, Dudiuk C, Cabeza MS, Gamarra S and Garcia-Effron G: Aspergillus fumigatus intrinsic fluconazole resistance is due to the naturally occurring T301I substitution in Cyp51Ap. Antimicrob Agents Chemother. 60:5420–5426. 2016. View Article : Google Scholar : PubMed/NCBI

Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV, Tanabe K, Niimi M, Goffeau A and Monk BC: Efflux-mediated antifungal drug resistance. Clin Microbiol Rev. 22:291–321. 2009. View Article : Google Scholar : PubMed/NCBI

Lamping E, Baret PV, Holmes AR, Monk BC, Goffeau A and Cannon RD: Fungal PDR transporters: Phylogeny, topology, motifs and function. Fungal Genet Biol. 47:127–142. 2010. View Article : Google Scholar

Kovalchuk A and Driessen AJM: Phylogenetic analysis of fungal ABC transporters. BMC Genomics. 11:1–21. 2010. View Article : Google Scholar : PubMed/NCBI

Chow EWL, Song Y, Chen J, Xu X, Wang J, Chen K, Gao J and Wang Y: The transcription factor Rpn4 activates its own transcription and induces efflux pump expression to confer fluconazole resistance in Candida auris. mBio. 14:e02688–e02623. 2023. View Article : Google Scholar : PubMed/NCBI

Garcia A, Huh EY and Lee SC: Serine/Threonine phosphatase calcineurin orchestrates the intrinsic resistance to micafungin in the human-pathogenic fungus mucor circinelloides. Antimicrob Agents Chemother. 67:e00686–e00622. 2023. View Article : Google Scholar : PubMed/NCBI

Al-Hatmi AMS, Meis JF and de Hoog GS: Fusarium: Molecular diversity and intrinsic drug resistance. PLoS Pathog. 12:e10054642016. View Article : Google Scholar : PubMed/NCBI

Delarze E and Sanglard D: Defining the frontiers between antifungal resistance, tolerance and the concept of persistence. Drug Resist Updat. 23:12–19. 2015. View Article : Google Scholar

Arastehfar A, Lass-Flörl C, Garcia-Rubio R, Daneshnia F, İlkit M, Boekhout T, Gabaldon T and Perlin DS: The quiet and underappreciated rise of drug-resistant invasive fungal pathogens. J Fungi (Basel). 6:1382020. View Article : Google Scholar : PubMed/NCBI

Delarze E, Brandt L, Trachsel E, Patxot M, Pralong C, Maranzano F, Chauvel M, Legrand M, Znaidi S, Bougnoux ME, et al: Identification and characterization of mediators of fluconazole tolerance in Candida albicans. Front Microbiol. 11:5911402020. View Article : Google Scholar

Koohi SR, Shankarnarayan SA, Galon CM and Charlebois DA: Identification and elimination of antifungal tolerance in Candida auris. Biomedicines. 11:8982023. View Article : Google Scholar : PubMed/NCBI

Delma FZ, Melchers WJG, Verweij PE and Buil JB: Wild-type MIC distributions and epidemiological cutoff values for 5-flucytosine and Candida species as determined by EUCAST broth microdilution. JAC Antimicrob Resist. 6:dlae1532024. View Article : Google Scholar

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Jones RN, Turnidge J and Diekema DJ: Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol. 48:52–56. 2010. View Article : Google Scholar

Espinel-Ingroff A, Colombo AL, Cordoba S, Dufresne PJ, Fuller J, Ghannoum M, Gonzalez GM, Guarro J, Kidd SE, Meis JF, et al: International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for fusarium species identified by molecular methods for the CLSI broth microdilution method. Antimicrob Agents Chemother. 60:1079–1084. 2016. View Article : Google Scholar : PubMed/NCBI

Levinson T, Dahan A, Novikov A, Paran Y, Berman J and Ben-Ami R: Impact of tolerance to fluconazole on treatment response in Candida albicans bloodstream infection. Mycoses. 64:78–85. 2021. View Article : Google Scholar : PubMed/NCBI

Yu S, Paderu P, Lee A, Eirekat S, Healey KR, Chen L, Perlin DS and Zhao Y: Histone acetylation regulator Gcn5 mediates drug resistance and virulence of Candida Glabrata. Microbiol Spectr. 10:e00963222022. View Article : Google Scholar : PubMed/NCBI

Garnaud C, García-Oliver E, Wang Y, Maubon D, Bailly S, Despinasse Q, Champleboux M, Govin J and Cornet M: The rim pathway mediates antifungal tolerance in Candida albicans through newly identified Rim101 transcriptional targets, including Hsp90 and Ipt1. Antimicrob Agents Chemother. 62:e01785–e01717. 2018. View Article : Google Scholar : PubMed/NCBI

Wiederhold NP: Antifungal resistance: Current trends and future strategies to combat. Infect Drug Resist. 10:249–259. 2017. View Article : Google Scholar

Lestrade PPA, Buil JB, van Der Beek MT, Kuijper EJ, van Dijk K, Kampinga GA, Rijnders BJA, Vonk AG, de Greeff SC, Schoffelen AF, et al: Paradoxal trends in azole-resistant Aspergillus fumigatus in a national multicenter surveillance program, the Netherlands, 2013–2018. Emerg Infect Dis. 26:1447–1455. 2020. View Article : Google Scholar : PubMed/NCBI

Edwards HM and Rhodes J: Accounting for the biological complexity of pathogenic fungi in phylogenetic dating. J Fungi (Basel). 7:6612021. View Article : Google Scholar : PubMed/NCBI

White TC, Marr KA and Bowden RA: Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Re. 11:382–402. 1998. View Article : Google Scholar

Gladyshev E: Repeat-Induced Point Mutation and Other Genome Defense Mechanisms in Fungi. Microbiol Spectr. 5:102017. View Article : Google Scholar

Hane JK, Williams AH, Taranto AP, Solomon PS and Oliver RP: Repeat-induced point mutation: A fungal-specific, endogenous mutagenesis process. Genet Transform Syst Fungi. 2:55–68. 2015. View Article : Google Scholar

Xiang MJ, Liu JY, Ni PH, Wang S, Shi C, Wei B, Ni YX and Ge HL: Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res. 13:386–393. 2013. View Article : Google Scholar : PubMed/NCBI

Biswas C, Marcelino VR, Van Hal S, Halliday C, Martinez E, Wang Q, Kidd S, Kennedy K, Marriott D, Morrissey CO, et al: Whole genome sequencing of Australian Candida glabrata isolates reveals genetic diversity and novel sequence types. Front Microbiol. 9:29462018. View Article : Google Scholar

Rocha EMF, Garcia-Effron G, Park S and Perlin DS: A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother. 51:4174–4176. 2007. View Article : Google Scholar : PubMed/NCBI

Lackner M, Tscherner M, Schaller M, Kuchler K, Mair C, Sartori B, Istel F, Arendrup MC and Lass-Flörl C: Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment. Antimicrob Agents Chemother. 58:3626–3635. 2014. View Article : Google Scholar : PubMed/NCBI

Diaz-Guerra TM, Mellado E, Cuenca-Estrella M and Rodriguez-Tudela JL: A point mutation in the 14α-Sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 47:1120–1124. 2003. View Article : Google Scholar : PubMed/NCBI

Katiyar SK, Alastruey-Izquierdo A, Healey KR, Johnson ME, Perlin DS and Edlind TD: Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: Implications for echinocandin resistance. Antimicrob Agents Chemother. 56:6304–6309. 2012. View Article : Google Scholar : PubMed/NCBI

Katiyar SK, Alastruey-Izquierdo A, Healey KR, Johnson ME, Perlin DS and Edlind TD: Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob Agents Chemother. 59:450–460. 2014. View Article : Google Scholar : PubMed/NCBI

Wirsching S, Moran GP, Sullivan DJ, Coleman DC and Morschhäuser J: MDR1-mediated drug resistance in Candida dubliniensis. Antimicrob Agents Chemother. 45:3416–3421. 2001. View Article : Google Scholar : PubMed/NCBI

Morschhäuser J, Barker KS, Liu TT, Blaß-Warmuth J, Homayouni R and Rogers PD: The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3:e1642007. View Article : Google Scholar

Abbes S, Mary C, Sellami H, Michel-Nguyen A, Ayadi A and Ranque S: Interactions between copy number and expression level of genes involved in fluconazole resistance in Candida glabrata. Front Cell Infect Microbiol. 3:742013. View Article : Google Scholar

Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, Denning DW, Loyse A and Boulware DR: Global burden of disease of HIV-associated cryptococcal meningitis: An updated analysis. Lancet Infect Dis. 17:873–881. 2017. View Article : Google Scholar : PubMed/NCBI

Priest SJ, Yadav V, Roth C, Dahlmann TA, Kück U, Magwene PM and Heitman J: Uncontrolled transposition following RNAi loss causes hypermutation and antifungal drug resistance in clinical isolates of Cryptococcus neoformans. Nat Microbiol. 7:1239–1251. 2022. View Article : Google Scholar

Torres EM, Sokolsky T, Tucker CM, Chan LY, Boselli M, Dunham MJ and Amon A: Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science. 317:916–924. 2007. View Article : Google Scholar : PubMed/NCBI

Williams BR, Prabhu VR, Hunter KE, Glazier CM, Whittaker CA, Housman DE and Amon A: Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science. 322:703–709. 2008. View Article : Google Scholar : PubMed/NCBI

Tsai HJ and Nelliat A: A double-edged sword: Aneuploidy is a prevalent strategy in fungal adaptation. Genes (Basel). 10:7872019. View Article : Google Scholar : PubMed/NCBI

Selmecki A, Forche A and Berman J: Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science. 313:367–370. 2006. View Article : Google Scholar : PubMed/NCBI

Ji H, Zhang W, Zhou Y, Zhang M, Zhu J, Song Y and Lü J: A three-dimensional model of lanosterol 14α-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem. 43:2493–2505. 2000. View Article : Google Scholar : PubMed/NCBI

Coste AT, Karababa M, Ischer F, Bille J and Sanglard D: TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell. 3:1639–1652. 2004. View Article : Google Scholar

Selmecki AM, Dulmage K, Cowen LE, Anderson JB and Berman J: Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLOS Genet. 5:e10007052009. View Article : Google Scholar

Ford CB, Funt JM, Abbey D, Issi L, Guiducci C, Martinez DA, Delorey T, Li BY, White TC, Cuomo C, et al: The evolution of drug resistance in clinical isolates of Candida albicans. Elife. 4:e006622015. View Article : Google Scholar : PubMed/NCBI

Mackey AI, Fillinger RJ, Hendricks PS, Thomson GJ, Cuomo CA, Bennett RJ and Anderson MZ: Aneuploidy confers a unique transcriptional and phenotypic profile to Candida albicans. Nat Commun. 16:32872025. View Article : Google Scholar : PubMed/NCBI

Sun LL, Li H, Yan TH, Fang T, Wu H, Cao YB, Lu H, Jiang YY and Yang F: Aneuploidy mediates rapid adaptation to a subinhibitory amount of fluconazole in Candida albicans. Microbiol Spectr. 11:e03016–e03022. 2023. View Article : Google Scholar : PubMed/NCBI

Sionov E, Lee H, Chang YC and Kwon-Chung KJ: Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 6:e10008482010. View Article : Google Scholar : PubMed/NCBI

Zhang Z, Sun L, Fu B, Deng J, Jia C, Miao M, Yang F, Cao YB and Yan TH: Aneuploidy underlies brefeldin A-induced antifungal drug resistance in Cryptococcus neoformans. Front Cell Infect Microbiol. 14:13977242024. View Article : Google Scholar

Hu G, Wang J, Choi J, Jung WH, Liu I, Litvintseva AP, Bicanic T, Aurora R, Mitchell TG, Perfect JR and Kronstad JW: Variation in chromosome copy number influences the virulence of Cryptococcus neoformans and occurs in isolates from AIDS patients. BMC Genomics. 12:1–19. 2011. View Article : Google Scholar

Sasse C, Dunkel N, Schäfer T, Schneider S, Dierolf F, Ohlsen K and Morschhäuser J: The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in andida albicans. Mol Microbiol. 86:539–556. 2012. View Article : Google Scholar

Heil CS: Loss of heterozygosity and its importance in evolution. J Mol Evol. 91:369–377. 2023. View Article : Google Scholar

Forche A, Abbey D, Pisithkul T, Weinzierl MA, Ringstrom T, Bruck D, Petersen K and Berman J: Stress alters rates and types of loss of heterozygosity in Candida albicans. mBio. 2:e00129–e00111. 2011. View Article : Google Scholar : PubMed/NCBI

Bennett RJ, Forche A and Berman J: Rapid mechanisms for generating genome diversity: Whole ploidy shifts, aneuploidy, and loss of heterozygosity. Cold Spring Harb Perspect Med. 4:a0196042014. View Article : Google Scholar : PubMed/NCBI

White TC: Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother. 41:1482–1487. 1997. View Article : Google Scholar : PubMed/NCBI

Luna-Tapia A, Willems HME, Parker JE, Tournu H, Barker KS, Nishimoto AT, Rogers PD, Kelly SL, Peters BM and Palmer GE: Loss of Upc2p-inducible ERG3 transcription is sufficient to confer niche-specific azole resistance without compromising Candida albicans pathogenicity. mBio. 9:e00225–e00218. 2018. View Article : Google Scholar : PubMed/NCBI

Rustad TR, Stevens DA, Pfaller MA and White TC: Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology. 148:1061–1072. 2002. View Article : Google Scholar : PubMed/NCBI

Gambhir N, Harris SD and Everhart SE: Evolutionary significance of fungal hypermutators: Lessons learned from clinical strains and implications for fungal plant pathogens. mSphere. 7:e00087–e00022. 2022. View Article : Google Scholar : PubMed/NCBI

Healey KR, Ortigosa CJ, Shor E and Perlin DS: Genetic drivers of multidrug resistance in Candida glabrata. Front Microbiol. 7:19952016. View Article : Google Scholar

Healey KR, Zhao Y, Perez WB, Lockhart SR, Sobel JD, Farmakiotis D, Kontoyiannis DP, Sanglard D, Taj-Aldeen SJ, Alexander BD, et al: Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nat Commun. 7:111282016. View Article : Google Scholar : PubMed/NCBI

Helmstetter N, Chybowska AD, Delaney C, Da Silva Dantas A, Gifford H, Wacker T, Munro C, Warris A, Jones B, Cuomo CA, et al: Population genetics and microevolution of clinical Candida glabrata reveals recombinant sequence types and hyper-variation within mitochondrial genomes, virulence genes, and drug targets. Genetics. 221:iyac0312022. View Article : Google Scholar : PubMed/NCBI

Vale-Silva L, Beaudoing E, Tran VDT and Sanglard D: Comparative genomics of two sequential Candida glabrata clinical isolates. G3 (Bethesda). 7:2413–2426. 2017. View Article : Google Scholar : PubMed/NCBI

Boyce KJ, Wang Y, Verma S, Shakya VPS, Xue C and Idnurm A: Mismatch repair of DNA replication errors contributes to microevolution in the pathogenic fungus Cryptococcus neoformans. mBio. 8:e00595–e00517. 2017. View Article : Google Scholar : PubMed/NCBI

Dos Reis TF, Silva LP, de Castro PA, do Carmo RA, Marini MM, da Silveira JF, Ferreira BH, Rodrigues F, Lind AL, Rokas A and Goldman GH: The Aspergillus fumigatus mismatch repair MSH2 homolog is important for virulence and azole resistance. mSphere. 4:e00416–e00419. 2019. View Article : Google Scholar : PubMed/NCBI

Ke W, Xie Y, Chen Y, Ding H, Ye L, Qiu H, Li H, Zhang L, Chen L, Tian X, et al: Fungicide-tolerant persister formation during cryptococcal pulmonary infection. Cell Host Microbe. 32:276–289. 2024. View Article : Google Scholar : PubMed/NCBI

Silva S, Rodrigues CF, Araújo D, Rodrigues ME and Henriques M: Candida Species Biofilms' antifungal resistance. J Fungi (Basel). 3:82017. View Article : Google Scholar : PubMed/NCBI

Massey J, Zarnowski R and Andes D: Role of the extracellular matrix in Candida biofilm antifungal resistance. FEMS Microbiol Rev. 47:fuad0592023. View Article : Google Scholar : PubMed/NCBI

Hommel B, Sturny-Leclère A, Volant S, Veluppillai N, Duchateau M, Yu CH, Hourdel V, Varet H, Matondo M, Perfect JR, et al: Cryptococcus neoformans resists to drastic conditions by switching to viable but non-culturable cell phenotype. PLoS Pathog. 15:e10079452019. View Article : Google Scholar : PubMed/NCBI

Alanio A, Vernel-Pauillac F, Sturny-Leclère A and Dromer F, Alanio A, Vernel-Pauillac F and Dromer F: Cryptococcus neoformans host adaptation: Toward biological evidence of dormancy. mBio. 6:e02580–e02514. 2015. View Article : Google Scholar : PubMed/NCBI

Hayes BME, Anderson MA, Traven A, van der Weerden NL and Bleackley MR: Activation of stress signalling pathways enhances tolerance of fungi to chemical fungicides and antifungal proteins. Cell Mol life Sci. 71:2651–2666. 2014. View Article : Google Scholar

Cruz MC, Goldstein AL, Blankenship JR, Del Poeta M, Davis D, Cardenas ME, Perfect JR, McCusker JH and Heitman J: Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J. 21:546–559. 2002. View Article : Google Scholar : PubMed/NCBI

LaFleur MD, Kumamoto CA and Lewis K: Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother. 50:3839–3846. 2006. View Article : Google Scholar : PubMed/NCBI

Fréalle E, Aliouat-Denis CM, Delhaes L, Hot D and Dei-Cas E: Transcriptomic insights into the oxidative response of stress-exposed Aspergillus fumigatus. Curr Pharm Des. 19:3713–3737. 2013. View Article : Google Scholar

Chang Z, Yadav V, Lee SC and Heitman J: Epigenetic mechanisms of drug resistance in fungi. Fungal Genet Biol. 132:1032532019. View Article : Google Scholar

Brandao FAS, Derengowski LS, Albuquerque P, Nicola AM, Silva-Pereira I and Poças-Fonseca MJ: Histone deacetylases inhibitors effects on Cryptococcus neoformans major virulence phenotypes. Virulence. 6:618–630. 2015. View Article : Google Scholar : PubMed/NCBI

Brandão F, Esher SK, Ost KS, Pianalto K, Nichols CB, Fernandes L, Bocca AL, Poças-Fonseca MJ and Alspaugh JA: HDAC genes play distinct and redundant roles in Cryptococcus neoformans virulence. Sci Rep. 8:52092018. View Article : Google Scholar

Ranjan K, Brandão F, Morais JAV, Muehlmann LA, Silva-Pereira I, Bocca AL, Matos LF and Poças-Fonseca MJ: The role of Cryptococcus neoformans histone deacetylase genes in the response to antifungal drugs, epigenetic modulators and to photodynamic therapy mediated by an aluminium phthalocyanine chloride nanoemulsion in vitro. J Photochem Photobiol B. 216:1121312021. View Article : Google Scholar : PubMed/NCBI

Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM, Hernday AD, Tuch BB, Andes DR and Johnson AD: A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell. 148:126–138. 2012. View Article : Google Scholar

Uppuluri P, Pierce CG, Thomas DP, Bubeck SS, Saville SP and Lopez-Ribot JL: The transcriptional regulator Nrg1p controls Candida albicans biofilm formation and dispersion. Eukaryot Cell. 9:1531–1537. 2010. View Article : Google Scholar

Li X, Cai Q, Mei H, Zhou X, Shen Y, Li D and Liu W: The Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans. J Antimicrob Chemother. 70:1993–2003. 2015. View Article : Google Scholar : PubMed/NCBI

Freitag M: Histone methylation by SET domain proteins in fungi. Annu Rev Microbiol. 71:413–439. 2017. View Article : Google Scholar

Honda S, Bicocca VT, Gessaman JD, Rountree MR, Yokoyama A, Yu EY, Selker JM and Selker EU: Dual chromatin recognition by the histone deacetylase complex HCHC is required for proper DNA methylation in Neurospora crassa. Proc Natl Acad Sci USA. 113:E6135–E6144. 2016. View Article : Google Scholar : PubMed/NCBI

Nai YS, Huang YC, Yen MR and Chen PY: Diversity of fungal DNA methyltransferases and their association with DNA methylation patterns. Front Microbiol. 11:6169222021. View Article : Google Scholar

Jeon J, Choi J, Lee GW, Park SY, Huh A, Dean RA and Lee YH: Genome-wide profiling of DNA methylation provides insights into epigenetic regulation of fungal development in a plant pathogenic fungus, Magnaporthe oryzae. Sci Rep. 5:85672015. View Article : Google Scholar : PubMed/NCBI

Catania S, Dumesic PA, Pimentel H, Nasif A, Stoddard CI, Burke JE, Diedrich JK, Cook S, Shea T, Geinger E, et al: Evolutionary persistence of DNA methylation for millions of years after ancient loss of a de novo methyltransferase. Cell. 180:263–277. 2020. View Article : Google Scholar

Baker KM, Hoda S, Saha D, Gregor JB, Georgescu L, Serratore ND, Zhang Y, Cheng L, Lanman NA, Briggs SD, et al: The Set1 histone H3K4 methyltransferase contributes to azole susceptibility in a species-specific manner by differentially altering the expression of drug efflux pumps and the ergosterol gene pathway. Antimicrob Agents Chemother. 66:e02250–e02221. 2022. View Article : Google Scholar : PubMed/NCBI

Khemiri I, Tebbji F, Burgain A and Sellam A: Regulation of copper uptake by the SWI/SNF chromatin remodeling complex in Candida albicans affects susceptibility to antifungal and oxidative stresses under hypoxia. FEMS Yeast Res. 24:foae0182024. View Article : Google Scholar : PubMed/NCBI

Salem-Bango Z, Price TK, Chan JL, Chandrasekaran S, Garner OB and Yang S: Fungal whole-genome sequencing for species identification: From test development to clinical utilization. J Fungi (Basel). 9:1832023. View Article : Google Scholar : PubMed/NCBI

Jiang S, Chen Y, Han S, Lv L and Li L: Next-generation sequencing applications for the study of fungal pathogens. Microorganisms. 10:18822022. View Article : Google Scholar : PubMed/NCBI

Liu SY, Lin JQ, Wu HL, Wang CC, Huang SJ, Luo YF, Sun JH, Zhou JX, Yan SJ, He JG, et al: Bisulfite sequencing reveals that Aspergillus flavus holds a hollow in DNA methylation. PLoS One. 7:e303492012. View Article : Google Scholar : PubMed/NCBI

Tan K and Wong KH: RNA polymerase II ChIP-seq-a powerful and highly affordable method for studying fungal genomics and physiology. Biophys Rev. 11:79–82. 2019. View Article : Google Scholar : PubMed/NCBI

Roemer T and Krysan DJ: Antifungal drug development: Challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med. 4:a0197032014. View Article : Google Scholar : PubMed/NCBI

Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell E, Bowyer P, Bromley M, Brüggemann R, Garber G, Cornely OA, et al: Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 20:557–571. 2022. View Article : Google Scholar

Grand View Research, . Antifungal drugs market size, share & growth report 2030 [Internet]. 2025.Available from:. https://www.grandviewresearch.com/industry-analysis/antifungal-drugs-market

Pyrpasopoulou A, Iosifidis E, Antachopoulos C and Roilides E: Antifungal drug dosing adjustment in critical patients with invasive fungal infections. J Emerg Crit Care Med. 3:10.21037/jeccm.2019.08.01. 2019. View Article : Google Scholar

Baracaldo-Santamaría D, Cala-Garcia JD, Medina-Rincón GJ, Rojas-Rodriguez LC and Calderon-Ospina CA: Therapeutic drug monitoring of antifungal agents in critically ill patients: Is there a need for dose optimisation? Antibiotics (Basel). 11:6452022. View Article : Google Scholar

Glampedakis E, Coste AT, Aruanno M, Bachmann D, Delarze E, Erard V and Lamoth F: Efficacy of antifungal monotherapies and combinations against Aspergillus calidoustus. Antimicrob Agents Chemother. 62:e01137–e01118. 2018. View Article : Google Scholar : PubMed/NCBI

Rieger CT, Ostermann H, Kolb HJ, Fiegl M, Huppmann S, Morgenstern N and Tischer J: A clinical cohort trial of antifungal combination therapy: Efficacy and toxicity in haematological cancer patients. Ann Hematol. 87:915–922. 2008. View Article : Google Scholar

Candoni A, Caira M, Cesaro S, Busca A, Giacchino M, Fanci R, Delia M, Nosari A, Bonini A, Cattaneo C, et al: Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study. Mycoses. 57:342–350. 2014. View Article : Google Scholar : PubMed/NCBI

Tu B, Yin G and Li H: Synergistic effects of vorinostat (SAHA) and azoles against Aspergillus species and their biofilms. BMC Microbiol. 20:1–7. 2020. View Article : Google Scholar

Rodrigues CF, Alves DF and Henriques M: Combination of Posaconazole and Amphotericin B in the treatment of Candida glabrata biofilms. Microorganisms. 6:1232018. View Article : Google Scholar : PubMed/NCBI

Vitale RG: Role of antifungal combinations in difficult to treat Candida infections. J Fungi (Basel). 7:7312021. View Article : Google Scholar : PubMed/NCBI

Fernandes CM, Dasilva D, Haranahalli K, McCarthy JB, Mallamo J, Ojima I and Del Poeta M: The future of antifungal drug therapy: Novel compounds and targets. Antimicrob Agents Chemother. 65:e01719–e01720. 2021. View Article : Google Scholar : PubMed/NCBI

Hodges MR, Tawadrous M, Cornely OA, Thompson GR III, Slavin MA, Maertens JA, Dadwal SS, Rahav G, Hazel S, Almas M, et al: Fosmanogepix for the treatment of invasive mold diseases caused by Aspergillus species and rare molds: A phase 2, open-label study (AEGIS). Clin Infect Dis. 9:ciaf1852025. View Article : Google Scholar

Oliver JD, Sibley GEM, Beckmann N, Dobb KS, Slater MJ, McEntee L, du Pré S, Livermore J, Bromley MJ, Wiederhold NP, et al: F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci USA. 113:12809–12814. 2016. View Article : Google Scholar : PubMed/NCBI

Tawfik DM, Dereux C, Tremblay JA, Boibieux A, Braye F, Cazauran JB, Rabodonirina M, Cerrato E, Guichard A, Venet F, et al: Interferon gamma as an immune modulating adjunct therapy for invasive mucormycosis after severe burn-A case report. Front Immunol. 13:8836382022. View Article : Google Scholar

Albahar F, Alhamad H, Assab MA, Abu-Farha R, Alawi L and Khaleel S: The impact of antifungal stewardship on clinical and performance measures: A global systematic review. Trop Med Infect Dis. 9:82023. View Article : Google Scholar : PubMed/NCBI

Kühbacher A, Birch M, Oliver JD and Gsaller F: Anti-Aspergillus activities of olorofim at sub-MIC levels during early-stage growth. Microbiol Spectr. 12:e03304–e03323. 2024. View Article : Google Scholar

Rhein J, Hullsiek KH, Tugume L, Nuwagira E, Mpoza E, Evans EE, Kiggundu R, Pastick KA, Ssebambulidde K, Akampurira A, et al: Adjunctive sertraline for HIV-associated cryptococcal meningitis: A randomised, placebo-controlled, double-blind phase 3 trial. Lancet Infect Dis. 19:843–851. 2019. View Article : Google Scholar : PubMed/NCBI

Liu Q, Guo X, Jiang G, Wu G, Miao H, Liu K, Chen S, Sakamoto N, Kuno T, Yao F and Fang Y: NADPH-cytochrome P450 reductase Ccr1 is a target of tamoxifen and participates in its antifungal activity via regulating cell wall integrity in fission yeast. Antimicrob Agents Chemother. 64:e00079–e00072. 2020. View Article : Google Scholar : PubMed/NCBI

Dai X, Liu X, Li J, Chen H, Yan C, Li Y, Liu H, Deng D and Wang X: Structural insights into the inhibition mechanism of fungal GWT1 by manogepix. Nat Commun. 15:91942024. View Article : Google Scholar : PubMed/NCBI

Schwebke JR, Sobel R, Gersten JK, Sussman SA, Lederman SN, Jacobs MA, Chappell BT, Weinstein DL, Moffett AH, Azie NE, et al: Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: A phase 3, randomized, controlled superiority trial (VANISH 303). Clin Infect Dis. 74:1979–1985. 2022. View Article : Google Scholar : PubMed/NCBI

(FDA) USF and DA, . Drug trials snapshots: brexafemme [Internet]. FDA; 2023, Available from:. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-brexafemme

Firooz A, Nafisi S and Maibach HI: Novel drug delivery strategies for improving econazole antifungal action. Int J Pharm. 495:599–607. 2015. View Article : Google Scholar : PubMed/NCBI

Nami S, Aghebati-Maleki A and Aghebati-Maleki L: Current applications and prospects of nanoparticles for antifungal drug delivery. EXCLI J. 20:562–584. 2021.PubMed/NCBI

Stone NRH, Bicanic T, Salim R and Hope W: Liposomal amphotericin B (AmBisome^®): A review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs. 76:485–500. 2016. View Article : Google Scholar : PubMed/NCBI

Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E, Rutakingirwa MK, Ssebambulidde K, Tugume L, Rhein J, et al: Single-dose liposomal amphotericin B treatment for cryptococcal meningitis. N Engl J Med. 386:1109–1120. 2022. View Article : Google Scholar : PubMed/NCBI

Empitu MA, Kadariswantiningsih IN and Shakri NM: Pharmacological strategies for targeting biofilms in otorhinolaryngologic infections and overcoming antimicrobial resistance. Biomed Rep. 22:952025. View Article : Google Scholar : PubMed/NCBI

Vera-González N, Bailey-Hytholt CM, Langlois L, de Camargo Ribeiro F, de Souza Santos EL, Junqueira JC and Shukla A: Anidulafungin liposome nanoparticles exhibit antifungal activity against planktonic and biofilm Candida albicans. J Biomed Mater Res Part A. 108:2263–2276. 2020. View Article : Google Scholar

El-Housiny S, Eldeen MA, El-Attar YA, Salem HA, Attia D, Bendas ER and El-Nabarawi MA: Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: Formulation and clinical study. Drug Deliv. 25:78–90. 2018. View Article : Google Scholar : PubMed/NCBI

Raad I, Mohamed JA, Reitzel RA, Jiang Y, Raad S, Al Shuaibi M, Chaftari AM and Hachem RY: Improved antibiotic-impregnated catheters with extended-spectrum activity against resistant bacteria and fungi. Antimicrob Agents Chemother. 56:935–941. 2012. View Article : Google Scholar : PubMed/NCBI